pyrrolamidolum
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2023 (NCT06169579)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Opioid receptors; mu/kappa/delta agonist
Dextromoramide is a powerful opioid analgesic approximately three times more potent than morphine but shorter acting.
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](CC(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)N1CCOCC1- Mol. weight
- 392.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833389 ↗
- ChEMBLCHEMBL3833311 ↗
Also known as
- (+)-1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine
- (+)-1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine
- 1-((3s)-3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)pyrrolidine
- 1-((3s)-3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)pyrrolidine
- (+)-4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine
- (+)-4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine
- 4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine
- 4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine
- d-2,2-diphenyl-3-methyl-4-morpholinobutyrylpyrrolidine
- d-2,2-diphenyl-3-methyl-4-morpholinobutyrylpyrrolidine
- dextromoramida
- dextromoramida
- dextromoramide
- dextromoramide
- dextromoramide
- dextromoramide
- dextromoramide
- dextromoramide
- dextromoramide
- dextromoramide tartrate
- dextromoramide tartrate
- dextromoramide tartrate
- dextromoramidum
- dextromoramidum
- dimorlin tartrate
- dimorlin tartrate
- moramide
- palfium
- palfium
- palphium
- palphium
- pyrrolamidol
- pyrrolamidol
- pyrrolamidol
- pyrrolamidolum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06360874 | Phase 1 | May 9, 2024 | Government of China, Huazhong University of Science and Technology |
| NCT06169579 | Phase 1 | Dec 31, 2023 | Government of China, Sun Yat-Sen University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1